This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sequist, L. V. Articles by Lynch, T. J. Search for Related Content PubMed PubMed Citation Articles by Sequist, L. V. Articles by Lynch, T. J.

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Authors' Affiliations: ¹ Cancer Center and Departments of ² Medicine and ³ Pathology, Massachusetts General Hospital; ⁴ Laboratory for Molecular Medicine, Harvard Medical School/Partners HealthCare Center for Genetics and Genomics; ⁵ Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of ⁶ Medicine and ⁷ Pathology, Brigham and Women's Hospital; ⁸ Department of Pathology, Harvard Medical School; and ⁹ Broad Institute at Massachusetts Institute of Technology and Harvard, Boston, Massachusetts

Requests for reprints: Lecia V. Sequist, Massachusetts General Hospital Cancer Center, Yawkey Center for Outpatient Care, 32 Fruit Street, 7th Floor, Boston, MA 02114. Phone: 617-726-7812; Fax: 617-726-0453; E-mail: LVSequist{at}Partners.org.

As the literature about epidermal growth factor receptor (EGFR) mutations grows and screening for mutations becomes increasingly integrated into clinical care, it is important to examine how best to do somatic mutational analyses and how best to use the test results in clinical decision making. We began offering mutation screening by comprehensive direct sequence analysis of exons 18 to 24 of the tyrosine kinase domain of EGFR in August 2004 as part of clinical cancer care and protocol therapy at our institutions. All identified potential mutations are confirmed with three to five independent PCRs of the original genomic DNA sample and, if not previously noted in the literature, are compared with the patient's germ-line DNA to ensure the finding is somatic. We formally analyzed the first 100 patients to undergo EGFR sequence analysis and found that testing was feasible and significantly affected the treatment of patients with non–small cell lung cancer (NSCLC). Patients harboring EGFR mutations were significantly more likely to receive recommendations for therapy with EGFR tyrosine kinase inhibitors (i.e., gefitinib or erlotinib) than patients without mutations. However, negative EGFR test results did not prevent physicians from administering these agents to selected patients. Ideally, a standardized technique for mutation testing could be developed, with demonstrated reproducibility and validity. Clinical trials incorporating molecular diagnostics are ongoing to assess the efficacy of EGFR tyrosine kinase inhibitors as first-line therapy for metastatic NSCLC and as adjuvant therapy for early-stage resected NSCLC. It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations.

This article has been cited by other articles:

				L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol., May 20, 2008; 26(15): 2442 - 2449. [Abstract] [Full Text] [PDF]

				A. R. Li, D. Chitale, G. J. Riely, W. Pao, V. A. Miller, M. F. Zakowski, V. Rusch, M. G. Kris, and M. Ladanyi EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression J. Mol. Diagn., May 1, 2008; 10(3): 242 - 248. [Abstract] [Full Text] [PDF]

				G D Smith, B E Chadwick, C Willmore-Payne, and J S Bentz Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis J. Clin. Pathol., April 1, 2008; 61(4): 487 - 493. [Abstract] [Full Text] [PDF]

				D. A. Eberhard, G. Giaccone, and B. E. Johnson Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994. [Abstract] [Full Text] [PDF]

				H. Suehisa, S. Toyooka, K. Hotta, A. Uchida, J. Soh, Y. Fujiwara, K. Matsuo, M. Ouchida, M. Takata, K. Kiura, et al. Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung J. Clin. Oncol., September 1, 2007; 25(25): 3952 - 3957. [Abstract] [Full Text] [PDF]

				M. Salto-Tellez A Case for Integrated Morphomolecular Diagnostic Pathologists Clin. Chem., July 1, 2007; 53(7): 1188 - 1190. [Full Text] [PDF]

				K. E. Finberg, L. V. Sequist, V. A. Joshi, A. Muzikansky, J. M. Miller, M. Han, J. Beheshti, L. R. Chirieac, E. J. Mark, and A. J. Iafrate Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features J. Mol. Diagn., July 1, 2007; 9(3): 320 - 326. [Abstract] [Full Text] [PDF]

				L. V. Sequist, V. A. Joshi, P. A. Janne, A. Muzikansky, P. Fidias, M. Meyerson, D. A. Haber, R. Kucherlapati, B. E. Johnson, and T. J. Lynch Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist, January 1, 2007; 12(1): 90 - 98. [Abstract] [Full Text] [PDF]